Pediatric Clinical Trials

Pediatric Brain Tumor

If you would like to inquire about all open trials, please contact 919.684.3401.

3 trials identified.

PBTC-029B: A Phase 1 and Phase II (B) and Re-Treatment (C) Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Phase: Phase II
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Jennifer King, RN
Phone: 919.668.5364
Purpose: This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory). Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Reference Number: 00023836
View this trial at ClinicalTrials.gov

PBTC-039: Phase II Study of Peginterferon alfa-2b (SYLATRON) for Pediatric Patients with Unresectable or Recurrent Craniopharyngioma
Phase: Phase II
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Jennifer King, RN
Phone: 919.668.5364
Purpose: This phase II trial studies how well peginterferon alfa-2b works in treating younger patients with craniopharyngioma that is recurrent or cannot be removed by surgery. Peginterferon alfa-2b may interfere with the growth of tumor cells and slow the growth of craniopharyngioma.
Reference Number: 00051755
View this trial at ClinicalTrials.gov

PBTC-042: Phase I Study of CDK 4-6 Inhibitor PD-0332991 (palbociclib; IBRANCE) in Children with Recurrent, Progressive or Refractory Central Nervous System Tumors
Phase: Phase I
Sponsor: Cooperative Group Initiated
Principal Investigator: David Vanmater
Contact: Jennifer King, RN
Phone: 919.668.5364
Purpose: This phase I trial studies the side effects and best dose of palbociclib isethionate in treating younger patients with central nervous system tumors that have grown, come back, or not responded to treatment. Palbociclib isethionate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Reference Number: 00054303
View this trial at ClinicalTrials.gov